196 related articles for article (PubMed ID: 12087603)
1. Treatment costs of venlafaxine and selective serotonin-reuptake inhibitors for depression and anxiety.
Wan GJ; Crown WH; Berndt ER; Finkelstein SN; Ling D
Manag Care Interface; 2002 Jun; 15(6):24-30. PubMed ID: 12087603
[TBL] [Abstract][Full Text] [Related]
2. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.
Griffiths RI; Sullivan EM; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
Pharmacoeconomics; 1999 May; 15(5):495-505. PubMed ID: 10537966
[TBL] [Abstract][Full Text] [Related]
3. Healthcare expenditure in patients treated with venlafaxine or selective serotonin reuptake inhibitors for depression and anxiety.
Wan GJ; Crown WH; Berndt ER; Finkelstein SN; Ling D
Int J Clin Pract; 2002; 56(6):434-9. PubMed ID: 12166541
[TBL] [Abstract][Full Text] [Related]
4. The pharmacoeconomics of venlafaxine in depression.
Morrow TJ
Am J Manag Care; 2001 Sep; 7(11 Suppl):S386-92. PubMed ID: 11570029
[TBL] [Abstract][Full Text] [Related]
5. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK; Kruzikas DT; McLaughlin TP
J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
[TBL] [Abstract][Full Text] [Related]
6. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Canadian provincial expenditures in depressed patients treated with venlafaxine XR versus SSRIs: the APEX Study.
Monfared AA; Han D; Sheehy O; Bexton B; Lelorier J
Curr Med Res Opin; 2006 Jan; 22(1):83-94. PubMed ID: 16393434
[TBL] [Abstract][Full Text] [Related]
8. One-year costs of second-line therapies for depression.
Sullivan EM; Griffiths RI; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
J Clin Psychiatry; 2000 Apr; 61(4):290-8. PubMed ID: 10830151
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder.
Einarson TR; Addis A; Iskedjian M
Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):286-96. PubMed ID: 10170453
[TBL] [Abstract][Full Text] [Related]
10. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.
Llorca PM; Fernandez JL
Int J Clin Pract; 2007 Apr; 61(4):702-10. PubMed ID: 17394446
[TBL] [Abstract][Full Text] [Related]
11. [Cost-effectiveness of venlafaxine for the treatment of depression and anxiety. Bibliographic review].
Baca Baldomero E; Rubio-Terrés C
Actas Esp Psiquiatr; 2006; 34(3):193-201. PubMed ID: 16736393
[TBL] [Abstract][Full Text] [Related]
12. Comparison of managed care charges among patients treated with selective serotonin reuptake inhibitors for premenstrual dysphoric disorder.
Endicott J; McLaughlin TP; Grudzinski AN
J Clin Psychiatry; 2003 Dec; 64(12):1511-6. PubMed ID: 14728114
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany.
Kulp W; von der Schulenburg JM; Greiner W
Eur J Health Econ; 2005 Dec; 6(4):317-21. PubMed ID: 16267659
[TBL] [Abstract][Full Text] [Related]
14. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.
Thase ME; Entsuah AR; Rudolph RL
Br J Psychiatry; 2001 Mar; 178():234-41. PubMed ID: 11230034
[TBL] [Abstract][Full Text] [Related]
15. Hyponatraemia in elderly psychiatric patients treated with Selective Serotonin Reuptake Inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit.
Kirby D; Harrigan S; Ames D
Int J Geriatr Psychiatry; 2002 Mar; 17(3):231-7. PubMed ID: 11921151
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression.
Stahl SM; Entsuah R; Rudolph RL
Biol Psychiatry; 2002 Dec; 52(12):1166-74. PubMed ID: 12488062
[TBL] [Abstract][Full Text] [Related]
17. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
Trivedi MH; Wan GJ; Mallick R; Chen J; Casciano R; Geissler EC; Panish JM
J Clin Psychopharmacol; 2004 Oct; 24(5):497-506. PubMed ID: 15349005
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine.
Sheehan DV; Eaddy M; Sarnes M; Vishalpura T; Regan T
J Clin Psychopharmacol; 2004 Oct; 24(5):544-8. PubMed ID: 15349013
[TBL] [Abstract][Full Text] [Related]
19. Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK.
Wade AG; Saragoussi D; Despiégel N; François C; Guelfucci F; Toumi M
Curr Med Res Opin; 2010 May; 26(5):1161-70. PubMed ID: 20297951
[TBL] [Abstract][Full Text] [Related]
20. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression.
Nulman I; Koren G; Rovet J; Barrera M; Pulver A; Streiner D; Feldman B
Am J Psychiatry; 2012 Nov; 169(11):1165-74. PubMed ID: 23128923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]